AnalyzeDirect Cao S, Durrani FA, Toth K, Rustum YM, Seshadri M. Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts. Oral Oncol. June 2011;47(6):459-466.
Full Text – Open Access
Publication Date
June 2011
How Analyze was Used
“All post processing and analysis were performed using Analyze™ (AnalyzeDirect, Overland Park, KS).”
Keywords
Angiogenesis Inhibitors/administration & dosage
Animals
Antibodies, Monoclonal/administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Agents/administration & dosage
Carcinoma, Squamous Cell/blood supply/drug therapy
Cell Line, Tumor
Drug Synergism
Drug Therapy, Combination/methods
Female
Head and Neck Neoplasms/blood supply/drug therapy
Humans
Mice
Mice, Nude
Xenograft Model Antitumor Assays
Author Affiliation(s)
Department of Cancer Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, US. (SC, FAD, KT, YMR)
Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, US. (SC)
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, US. (MS)
Department of Dentistry and Maxillofacial Prosthetics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, US. (MS)
ID# 740
Tags: Angiogenesis Inhibitors/administration & dosage, Animals, Antineoplastic Agents/administration & dosage, Combination Drug Therapy/methods, Drug Synergism, Female, Head and Neck Neoplasms/blood supply/drug therapy, Humanized Monoclonal Antibodies, Humans, Mice, Monoclonal Antibodies/administration & dosage, Nude Mice, Squamous Cell Carcinoma/blood supply/drug therapy, Tumor Cell Line, Xenograft Model Antitumor Assays